Improving Drug Development Programs with Novel Epigenomic Insights

• A deep dive into epigenomic biomarkers within the precision oncology toolkit, and how methylation-based signatures reveal tumour biology beyond genomics
• An overview of emerging data demonstrating where epigenomic biomarkers deliver the greatest impact for patient stratification and trial enrichment
• A discussion of Guardant Health’s expanding global testing capabilities and their role in advancing epigenomics in clinical care

Speakers:

Jean-Francois Martini

Senior Director, BioPharma Translational Strategy & Applications

Guardant Health